Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study

It is unknown whether stopping renin-angiotensin system (RAS) inhibitor therapy in patients with advanced CKD affects outcomes. We studied patients referred to nephrologist care, listed on the Swedish Renal Registry during 2007-2017, who developed advanced CKD (eGFR

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2021-02, Vol.32 (2), p.424-435
Hauptverfasser:	Fu, Edouard L, Evans, Marie, Clase, Catherine M, Tomlinson, Laurie A, van Diepen, Merel, Dekker, Friedo W, Carrero, Juan J
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiotensin Receptor Antagonists - administration & dosage Angiotensin-Converting Enzyme Inhibitors - administration & dosage Cardiovascular Diseases - epidemiology Clinical Epidemiology Female Glomerular Filtration Rate Humans Male Middle Aged Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - mortality Renal Insufficiency, Chronic - therapy Renal Replacement Therapy Renin-Angiotensin System Survival Rate Sweden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	It is unknown whether stopping renin-angiotensin system (RAS) inhibitor therapy in patients with advanced CKD affects outcomes. We studied patients referred to nephrologist care, listed on the Swedish Renal Registry during 2007-2017, who developed advanced CKD (eGFR
ISSN:	1046-6673 1533-3450
DOI:	10.1681/ASN.2020050682